TDMS Study 05142-04 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
T-BUTYL ALCOHOL
NTP Experiment-Test: 05142-04 Report: PEIRPT05
Study Type: CHRONIC Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
Facility: Southern Research Institute
Chemical CAS #: 75-65-0
Lock Date: 01/23/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 13 14 13 12
Natural Death 10 8 4 4
Accidently Killed 1 3 2 2
Survivors
Terminal Sacrifice 36 35 40 42
Natural Death 1
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (60) (60) (60) (60)
Squamous Cell Carcinoma 1 (2%)
Gallbladder (58) (59) (58) (56)
Intestine Large, Colon (57) (58) (58) (60)
Intestine Small, Duodenum (58) (57) (56) (60)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (57) (56) (57) (60)
Adenocarcinoma 2 (4%)
Intestine Small, Ileum (57) (57) (55) (60)
Adenocarcinoma 1 (2%)
Liver (59) (60) (59) (60)
Cholangiocarcinoma 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma 2 (3%)
Hepatocellular Carcinoma 16 (27%) 18 (30%) 12 (20%) 8 (13%)
Hepatocellular Carcinoma, Multiple 9 (15%) 8 (13%) 10 (17%) 4 (7%)
Hepatocellular Adenoma 17 (29%) 17 (28%) 16 (27%) 14 (23%)
Hepatocellular Adenoma, Multiple 12 (20%) 13 (22%) 15 (25%) 15 (25%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 3 (5%)
Mesentery (24) (17) (17) (12)
Cholangiocarcinoma, Metastatic, Liver 1 (4%) 1 (6%) 1 (8%)
Fibrosarcoma 1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (6%)
Histiocytic Sarcoma 1 (4%) 3 (25%)
Pancreas (59) (59) (59) (59)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hemangioma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (3%)
Salivary Glands (60) (60) (60) (60)
Stomach, Forestomach (60) (60) (59) (60)
Page 2
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 1 (2%) 2 (3%) 2 (3%)
Stomach, Glandular (60) (60) (59) (59)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Subcapsular, Adenoma 1 (2%) 1 (2%)
Subcapsular, Carcinoma 1 (2%)
Adrenal Medulla (60) (60) (60) (60)
Pheochromocytoma Benign 2 (3%)
Islets, Pancreatic (59) (59) (59) (59)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Parathyroid Gland (48) (56) (57) (50)
Pituitary Gland (56) (57) (60) (60)
Pars Distalis, Adenoma 11 (20%) 18 (32%) 15 (25%) 18 (30%)
Thyroid Gland (58) (60) (59) (59)
Bilateral, Follicular Cell, Adenoma 1 (2%)
C-Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 2 (3%) 3 (5%) 2 (3%) 8 (14%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (58) (58) (60) (59)
Cystadenoma 2 (3%) 3 (5%) 3 (5%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%)
Teratoma Benign 1 (2%)
Teratoma NOS 1 (2%)
Uterus (60) (60) (59) (59)
Granular Cell Tumor Malignant 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Page 3
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Leiomyoma 1 (2%)
Endometrium, Polyp Stromal 1 (2%) 1 (2%) 1 (2%)
Endometrium, Polyp Stromal, Multiple, Two 1 (2%)
Endometrium, Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (59) (60) (60) (60)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (3%)
Lymph Node (19) (12) (6) (13)
Bronchial, Cholangiocarcinoma, Metastatic,
Liver 1 (5%)
Iliac, Histiocytic Sarcoma 1 (8%)
Mediastinal, Cholangiocarcinoma, Metastatic,
Liver 1 (5%) 1 (8%) 1 (8%)
Mediastinal, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (8%)
Mediastinal, Histiocytic Sarcoma 1 (8%) 1 (8%)
Pancreatic, Histiocytic Sarcoma 1 (8%)
Renal, Hemangiosarcoma 1 (8%) 1 (17%)
Renal, Histiocytic Sarcoma 1 (8%)
Lymph Node, Mandibular (59) (58) (59) (57)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node, Mesenteric (56) (59) (57) (57)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Spleen (59) (60) (59) (59)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 3 (5%)
Thymus (57) (58) (53) (58)
Histiocytic Sarcoma 1 (2%)
Thymocyte, Thymoma Benign 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (60) (60) (60)
Adenocarcinoma 1 (2%)
Skin (60) (60) (60) (60)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (3%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (2) (1) (1) (2)
Cholangiocarcinoma, Metastatic, Liver 1 (50%) 1 (100%) 1 (50%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
Histiocytic Sarcoma 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
Histiocytic Sarcoma 1 (2%)
Meningioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (59) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 2 (3%) 3 (5%) 5 (8%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (3%) 2 (3%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple, Two 1 (2%) 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (7%) 3 (5%) 5 (8%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (3%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%) 1 (2%)
Nose (60) (60) (60) (60)
Submucosa, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1)
Pinna, Hemangioma 1 (100%)
Harderian Gland (3) (1) (1) (2)
Adenoma 1 (33%) 1 (100%) 1 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (59) (60) (59) (60)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (59) (60) (59) (57)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Page 5
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 3 (5%) 1 (2%) 3 (5%)
Lymphoma Malignant Lymphocytic 2 (3%)
Lymphoma Malignant Mixed 15 (25%) 22 (37%) 21 (35%) 14 (23%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 54 54 55 53
Total Primary Neoplasms 107 120 115 111
Total Animals with Benign Neoplasms 38 40 44 45
Total Benign Neoplasms 50 61 65 73
Total Animals with Malignant Neoplasms 41 45 40 31
Total Malignant Neoplasms 57 59 49 38
Total Animals with Metastatic Neoplasms 5 5 6 2
Total Metastatic Neoplasm 10 13 14 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Early Deaths
Moribund Sacrifice 20 14 19 21
Natural Death 13 8 6 22
Accidently Killed 2 1
Survivors
Terminal Sacrifice 27 36 34 17
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (55) (57) (59) (54)
Histiocytic Sarcoma 1 (2%)
Intestine Small, Duodenum (56) (56) (57) (56)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (56) (56) (57) (55)
Adenocarcinoma 1 (2%) 2 (4%)
Hemangioma 1 (2%)
Polyp Adenomatous 1 (2%)
Intestine Small, Ileum (56) (56) (57) (55)
Polyp Adenomatous 1 (2%)
Liver (59) (60) (59) (59)
Cholangiocarcinoma 1 (2%) 1 (2%)
Hemangioma 2 (3%)
Hemangiosarcoma 3 (5%) 5 (8%) 2 (3%)
Hepatoblastoma 2 (3%) 2 (3%) 4 (7%) 2 (3%)
Hepatoblastoma, Multiple 1 (2%)
Hepatocellular Carcinoma 14 (24%) 14 (23%) 21 (36%) 14 (24%)
Hepatocellular Carcinoma, Multiple 11 (19%) 15 (25%) 14 (24%) 5 (8%)
Hepatocellular Adenoma 18 (31%) 15 (25%) 22 (37%) 13 (22%)
Hepatocellular Adenoma, Multiple 21 (36%) 26 (43%) 22 (37%) 13 (22%)
Hepatocellular Adenoma, Multiple, Two 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Mesentery (5) (6) (7) (4)
Hemangiosarcoma 1 (17%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (17%)
Histiocytic Sarcoma 1 (20%) 1 (14%)
Sarcoma 1 (20%)
Pancreas (58) (59) (59) (57)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Stomach, Forestomach (59) (59) (59) (58)
Page 8
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 2 (3%)
Stomach, Glandular (59) (59) (59) (57)
Sarcoma, Metastatic, Mesentery 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Pericardium, Cholangiocarcinoma, Metastatic,
Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Adenoma 1 (2%) 2 (3%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Subcapsular, Adenoma 3 (5%) 5 (8%) 2 (3%)
Islets, Pancreatic (59) (59) (59) (57)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (52) (57) (56) (53)
Pars Distalis, Adenoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (60) (59) (59) (57)
Follicular Cell, Adenoma 1 (2%) 4 (7%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1)
Thoracic, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (100%)
Thoracic, Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (60)
Histiocytic Sarcoma 2 (3%)
Testes (60) (60) (60) (59)
Interstitial Cell, Adenoma 1 (2%)
Page 9
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (9) (5) (1) (1)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (11%)
Mediastinal, Cholangiocarcinoma, Metastatic,
Liver 1 (20%)
Mediastinal, Histiocytic Sarcoma 1 (11%)
Renal, Histiocytic Sarcoma 1 (11%)
Lymph Node, Mandibular (57) (59) (58) (56)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (59) (58) (57) (56)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
Spleen (59) (59) (59) (57)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 2 (3%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (3%) 1 (2%)
Thymus (53) (54) (55) (52)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymocyte, Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Basal Cell Adenoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Hemangioma 2 (3%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Osteoma 1 (2%)
Skeletal Muscle (2) (1)
Hemangiosarcoma 1 (100%)
Sarcoma, Metastatic, Mesentery 1 (50%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Alveolar/Bronchiolar Adenoma 10 (17%) 6 (10%) 6 (10%) 4 (7%)
Alveolar/Bronchiolar Adenoma, Multiple, Two 2 (3%)
Alveolar/Bronchiolar Carcinoma 4 (7%) 2 (3%) 3 (5%) 2 (3%)
Carcinoma 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (7%) 3 (5%) 2 (3%) 3 (5%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Mediastinum, Hemangiosarcoma 1 (2%)
Pleura, Cholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (2)
Pinna, Fibrosarcoma 1 (50%)
Harderian Gland (10) (3) (3) (1)
Adenoma 8 (80%) 3 (100%) 2 (67%) 1 (100%)
Carcinoma 2 (20%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (58) (59) (57)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Adenocarcinoma 1 (2%) 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Urinary Bladder (59) (59) (58) (59)
Hemangioma 1 (2%) 1 (2%)
Page 11
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 2 (3%) 1 (2%) 2 (3%)
Lymphoma Malignant Mixed 7 (12%) 2 (3%) 5 (8%) 2 (3%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05142-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC T-BUTYL ALCOHOL Date: 05/20/95
Route: DOSED WATER Time: 08:27:30
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 0.5% 1.0% 2.0%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 56 56 56 43
Total Primary Neoplasms 123 118 119 68
Total Animals with Benign Neoplasms 47 49 50 31
Total Benign Neoplasms 69 67 62 36
Total Animals with Malignant Neoplasms 41 40 43 27
Total Malignant Neoplasms 54 51 57 32
Total Animals with Metastatic Neoplasms 8 4 2 4
Total Metastatic Neoplasm 20 7 2 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------